Non-Small Cell Lung Cancer Excellence Forum

Non-Small Cell Lung Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Maria Werner-Wasik, MD, Sidney Kimmel Cancer Center

Videos

Chemoimmunotherapy and the Changing Landscape of Preoperative Treatment for Stage III Non-Small Cell Lung Cancer

03/20/2023

At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.

At the 2023 ACRO Radiation...

03/20/2023

Oncology

Videos

How Preoperative Chemoimmunotherapy May Change Management of Patients With Stage III Non-Small Cell Lung Cancer

03/20/2023

At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.

At the 2023 ACRO Radiation...

03/20/2023

Oncology

Alison Schram, MD, Memorial Sloan Kettering Cancer Center

Videos

Targeting Class II/III Alterations in BRAF Inhibitors

03/16/2023

At 2023 ESMO Targeted Anticancer Therapies Congress, Alison Schram, MD, discusses the class II/III alterations of BRAF inhibitors.

At 2023 ESMO Targeted Anticancer...

03/16/2023

Oncology

Lyudmila Bazhenova, MD, University of California San Diego

Videos

The Importance of Biomarker Testing for Patients With NSCLC

01/05/2023

Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss their approaches to biomarker testing for patients newly diagnosed with NSCLC, the role of tissue vs liquid biopsy, and how these biomarkers are used to inform treatment decisions.

Edward Garon, MD, and Lyudmila...

01/05/2023

Oncology

Lyudmila Bazhenova, MD, Professor of Medicine at the University of California, San Diego, California

Videos

Dabrafenib Plus Trametinib for Patients With BRAF-V600E Mutated Lung Cancer

12/02/2022

Lyudmila Bazhenova, MD, reviews the treatment options for BRAF mutations in lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.

Lyudmila Bazhenova, MD, reviews...

12/02/2022

Oncology

Edward Garon, MD, David Geffen School of Medicine - UCLA, Los Angeles, California

Videos

Pembrolizumab Monotherapy for Patients With HighPD-L1 Non-Small Cell Lung Cancer

12/02/2022

Edward Garon, MD, discusses the treatment of patients with non-small cell lung cancer and a PD-L1 expression of ≥50%, a topic he debated at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.

Edward Garon, MD, discusses the...

12/02/2022

Oncology

Videos

Differentiating Targets and Therapies for Patients With HER2-Mutant Lung Cancer

11/29/2022

Lyudmila Bazhenova, MD, University of California, San Diego, California, discusses the management and treatment of patients with HER2-mutated non-small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung...

Lyudmila Bazhenova, MD,...

11/29/2022

Oncology

Videos

Tremelimumab Added to Durvalumab and Chemotherapy Demonstrates Long-Term OS Benefit in Metastatic NSCLC

11/11/2022

Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...

Melissa Johnson, MD, discusses...

11/11/2022

Oncology

Videos

Sotorasib Significantly Improves PFS vs Docetaxel in Patients With KRAS G12C-Mutated NSCLC

11/10/2022

Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.

Melissa Johnson, MD, discusses...

11/10/2022

Oncology

Raj Veluswamy, MD, Icahn School of Medicine, New York

Videos

NTRK: Front-Line and Second-Line Treatment Options for Patients With NSCLC

10/15/2022

Rajwanth Veluswamy, MD, provides an overview of his presentation at Great Debates and Updates in Lung Cancer covering front-line and second-line treatment options for patients with NSCLC and NTRK fusions.

Rajwanth Veluswamy, MD, provides...

10/15/2022

Oncology

Recent News

FDA Approval

FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer

10/03/2024

Stephanie Holland ;

Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...

Based on results from the...

10/03/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology